Aimmune Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

27.05.18	An Ear To The Pharma: 12 Stocks To Watch (AIMT, TXMD, MDGL…) (RTTNews)
15.05.18	Aimmune Therapeutics to Present Data on Peanut Allergy at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018 (Businesswire)
09.05.18	Aimmune Therapeutics to Participate in Four Upcoming Investor Conferences in May and June (Businesswire)
08.05.18	Aimmune Therapeutics Announces First Quarter 2018 Financial Results (Businesswire)
07.03.18	Aimmune Therapeutics to Participate in Four Investor Conferences in March (Businesswire)
04.03.18	Aimmune Therapeutics Presents Results From the Positive, Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy at AAAAI-WAO (Businesswire)
02.03.18	Aimmune Therapeutics Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock (Businesswire)
27.02.18	Aimmune Therapeutics to Host Analyst and Investor Event Following Oral Late-Breaking Presentation of Phase 3 PALISADE Results on Sunday, March 4, at the AAAAI-WAO Joint Congress in Orlando (Businesswire)
26.02.18	Aimmune Therapeutics Announces Closing of Public Offering of Common Stock (Businesswire)
22.02.18	ACIP Backs HEPLISAV-B, GMED Hits New High, GWPH's Focal Seizures Trial Fails (RTTNews)
22.02.18	Aimmune Therapeutics Announces Pricing of Public Offering of Common Stock (Businesswire)
21.02.18	AIMT Meets Study Goals, TTPH Keeps Hopes Alive, Opportunities Galore For TXMD (RTTNews)
20.02.18	Aimmune Therapeutics Announces Proposed Public Offering of Common Stock (Businesswire)
20.02.18	Investors Going Nuts For Aimmune (RTTNews)
20.02.18	Aimmune Therapeutics’ Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut Allergy (Businesswire)
18.02.18	An Ear To The Pharma: 5 Stocks To Watch This Week (RTTNews)
14.02.18	Aimmune Therapeutics Expands Scientific Advisory Board With Appointments of George du Toit, M.B., B.Ch., and Wayne Shreffler, M.D., Ph.D. (Businesswire)
12.02.18	Aimmune Therapeutics Announces Presentations at 2018 AAAAI-WAO Joint Congress (Businesswire)
12.02.18	Will These 4 Pharma Stocks Be Loved Or Dumped This Month? (RTTNews)
10.01.18	Aimmune Therapeutics Broadens and Extends Supply Agreement With Golden Peanut and Tree Nuts for AR101 for Peanut Allergy (Businesswire)
08.01.18	Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data from Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy (Businesswire)
03.01.18	Aimmune Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference (Businesswire)
07.12.17	Aimmune Therapeutics to Participate in the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14 (Businesswire)
20.11.17	Aimmune Therapeutics to Host Investor Symposium on Peanut Allergy Treatment with Leading Expert Allergists on Friday, December 1 (Businesswire)
06.11.17	Aimmune Therapeutics Announces Third Quarter 2017 Financial Results and Planned Retirement of CEO by the End of 2018 (Businesswire)
01.11.17	Aimmune Therapeutics to Participate in Four Investor Conferences in November (Businesswire)
31.10.17	Aimmune Therapeutics Announces Publication in The Journal of Allergy and Clinical Immunology: In Practice of Positive AR101 Data from ARC001 Phase 2 Clinical Trial (Businesswire)
24.10.17	AIMT Gains As DBVT Bleeds, PETS Gets Attention, FLDM On Watch (RTTNews)
23.10.17	DBVT Disappoints, GSK Gets Greenlight, AIMT Catches Eyes, FDA Snubs ATRS (RTTNews)
19.10.17	Aimmune Therapeutics to Present Data on Peanut Allergy at ACAAI and PAAM Medical Meetings (Businesswire)
06.09.17	Aimmune Therapeutics to Participate in Three Investor Conferences in September (Businesswire)
13.06.17	XLRN's DART Misses Mark, RGLS Makes Cuts In Pipeline, FDA Snubs CHRS (RTTNews)
29.11.16	FOLD Shrinks, JAZZ On Right Track, NVLS Choked Up, AAAP On Watch, NVRO Sues BSX (RTTNews)
04.11.16	Aimmune Therapeutics Announces $145 Million Equity Investment by Nestlé Health Science, Demonstrating Shared Commitment to Advancing Food Allergy Therapeutics (Businesswire)
13.06.16	Aimmune Therapeutics Announces Phase 2 Extended Maintenance Data Supporting Safety and Tolerability Profile of AR101 for Peanut Allergy (Businesswire)
07.06.16	Aimmune Therapeutics Announces Late-Breaker Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2016 (Businesswire)
16.05.16	Aimmune Therapeutics Announces First Quarter 2016 Financial Results and Provides Corporate Update (Businesswire)
07.03.16	TNXP Awaits Data In Q2, LLY Uncovers Ixekizumab's Potential, High Five For MNOV (RTTNews)
12.01.16	ONCE Braces For Busy Year, ELOS Rises After Hours, GWPH Under Scanner (RTTNews)
07.10.15	Aimmune Therapeutics Receives EMA Decision Agreeing With PIP for AR101 for the Treatment of Peanut Allergy (Businesswire)
02.09.15	Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference (Businesswire)
01.09.15	Earnings Reported After The Bell Aug. 31 (RTTNews)
01.09.15	AIMT Is Nothing To Sneeze At, AGRX Secured, TiGenix Admired, ICPT Gets FDA Date (RTTNews)
06.08.15	Aimmune Therapeutics Prices IPO At $16.00/shr (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

14.10.20		Nestlé-Aktie dreht ins Minus: Nestlé schliesst Übernahme von Aimmune Therapeutics ab
13.10.20		Nestlé-Aktie kaum bewegt: Nestlé hält nach Ablauf der Zeichnungsfrist 84 Prozent an Aimmune Therapeutics
31.08.20		Nestlé will Aimmune Therapeutics kaufen - Nestlé-Aktie leichter - Aimmune Therapeutics +170 Prozent

14.10.20

Nestlé-Aktie dreht ins Minus: Nestlé schliesst Übernahme von Aimmune Therapeutics ab

13.10.20

Nestlé-Aktie kaum bewegt: Nestlé hält nach Ablauf der Zeichnungsfrist 84 Prozent an Aimmune Therapeutics

31.08.20

Nestlé will Aimmune Therapeutics kaufen - Nestlé-Aktie leichter - Aimmune Therapeutics +170 Prozent

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Part Grp Hldg	1’331.00	5.59 %	K V
Logitech Intl	80.46	3.45 %	K V
Lonza Grp	554.40	2.33 %	K V
Sonova Hldg	299.50	1.77 %	K V
CieFinRichemont	140.70	1.19 %	K V
Givaudan	3’881.00	-0.18 %	K V
ABB	49.51	-0.20 %	K V
Zurich Insur Gr	546.80	-0.22 %	K V
Sika	216.20	-0.69 %	K V
Kuehne+Nagel Int	207.80	-0.76 %	K V

Nachrichten zu Aimmune Therapeutics Inc

Aktien Top/Flop

Aimmune Therapeutics Peer Group Nachrichten

Meistgelesene Nachrichten